Horizon Europe Marie Skłodowska-Curie (2024) Postdoctoral Fellowships

  • Full Time
  • London
  • Posted 4 months ago

Job title:

Horizon Europe Marie Skłodowska-Curie (2024) Postdoctoral Fellowships

Company

Job description

(WHRI) is part of the Faculty of Medicine and Dentistry at Queen Mary University of London. We are the largest multidisciplinary pharmacological research institutes in the UK University sector and one of the largest in Europe with over 530 clinicians and scientists from 45 countries. Our primary research focus and excellence lies in our basic, translational and clinical research in cardiovascular, endocrine and inflammation. We are home to international excellence in critical care and perioperative medicine research and have successfully combined talents from different disciplines, such as genomics, cell biology, pharmacology, with translational bench-to-patient studies and large-scale clinical trials, all with the ambition of therapeutic innovation. Our innovative research environment and close collaboration with Barts Health NHS Trust and healthcare partners across East London gives us a unique opportunity to translate and extend basic and clinical research into therapeutics that benefit the local community and beyond.We are inviting expressions of interests (EOIs) from exceptional candidates who wish to apply for a MSCA Postdoctoral Fellowship in one of the following topics:

  • Drugging efferocytosis as a strategy for mitigating chronic inflammatory diseases
  • Immunometabolic cross-talk in the inflamed diabetic heart
  • Impact of diet and inflammation during pregnancy on maternal and fetal health
  • Investigating impaired calcium handling in cardiomyopathy of inflammatory arthritis
  • Novel therapeutic strategies for clearance of neutrophil extracellular traps
  • Regulation of inflammation resolution by clinically active South Africa medicinal plants: analytical and pharmacological characterisation
  • Resolution Pharmacology: targeting cardiac metabolism to mitigate the cardiomyopathy of inflammatory arthritis
  • The role of SGLT2 inhibitor in a novel “two-hit” model of HFpEF induced by arthritis and metabolic syndrome
  • Therapeutic Potential of Modulating Myocardial ATP Homeostasis in Heart Failure (HFpEF and HFreF)
  • Therapeutic Potential of Modulating Myocardial ATP Homeostasis in Type 2 Diabetes
  • Uncovering Protective Mechanisms that Reprogram Immune Cells to Enhance Resilience and Limit Disease
  • Do sex differences in inflammatory resolution drive differences in atherosclerosis development
  • Dissecting the mechanises underlying sex differences in susceptibility to cardiovascular disease
  • Investigating novel NO-delivery methods for preventing renal dysfunction
  • Assessing lifestyle factors in diverse populations to inform appropriate behavioural interventions for reducing cardiovascular disease risk
  • Defining biological mechanisms driving trajectories of severe mental illness
  • Exploring the causal landscape of complex traits and diseases
  • Exploring the role of rare genetic variants with hypertension
  • Genes essential for organism development – clinical and functional genetics
  • Genetic Analyses to Identify Specific Drug Targets for AI-derived Sub-Phenotypes of Hypertension
  • Harnessing redox signalling for therapeutic purposes
  • Identifying gene-by-lifestyle interactions that could moderate cardiovascular disease risk in large scale, multi-ancestry biobanks
  • Investigating the Pharmacogenetic Contribution to the Response to Statin Therapy
  • Machine learning approaches for an integrated, multi-modal risk score for improved coronary artery disease prediction in diverse populations
  • Multi-modal AI data integration for disease prediction
  • Oxidant sensing and signalling
  • Understanding neuro-immune complexity in depression in physical illnesses
  • Understanding relationships between electrocardiogram biomarkers with atrial fibrillation and ventricular arrhythmias
  • Adrenocortical stem cells in adrenal physiology and pathology
  • Development of novel targeted therapies for adrenal cancer
  • Genetics of adrenal insufficiency – finding new causal genes/mechanisms
  • Iron metabolism in the adrenal gland
  • Role of neuroendocrine transcriptional regulation in disorders of human puberty
  • Defining the neuroimmune basis of chemotherapy induced neuropathic pain
  • Investigating the contribution of fibroblast-neuron crosstalk in diseased synovium of patients with refractory rheumatoid arthritis
  • Investigating the mechanistic basis of sex differences in osteoarthritis pain
  • The biomechanical predictors of lower limb injury outcome – a cohort study within the highly phenotyped Biomedical Research Centre cohort
  • Targeting endothelial-to-mesenchymal transition in chronic fibrotic diseases
  • Understanding the roles of Atypical Chemokine Receptors in regulating endothelial cell identity in health and disease

The scheme is open to any nationality and covers salary plus travel and family allowance for two years. Candidates need to have a PhD and must not have resided in the United Kingdom from more than 12 months in the past three years.The MSCA Postdoctoral Fellowships 2024 call is open and deadline is 11th September 2024. Successful projects will start in Spring 2025.The Deadline for receipt of EOIs is midnight on 31st July (BST). For the application from and instructions please emailShare this page

Expected salary

Location

London

Job date

Fri, 05 Jul 2024 02:58:36 GMT

To help us track our recruitment effort, please indicate in your email/cover letter where (globalvacancies.org) you saw this job posting.

To apply for this job please visit jobviewtrack.com.

Job Location